Patents by Inventor Tyler Jacks

Tyler Jacks has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210361603
    Abstract: The present disclosure relates to a method of treating a subject having cancer that includes selecting a subject having cancer associated with a deregulated NRF2/KEAP1 pathway and administering to the selected subject one or more inhibitors comprising a glutamine transporter inhibitor; a GPD2 inhibitor; or combination(s) thereof.
    Type: Application
    Filed: February 6, 2018
    Publication date: November 25, 2021
    Applicants: New York University, Massachusetts Institute Of Technology
    Inventors: Thales PAPAGIANNAKOPOULOS, Tyler JACKS, Rodrigo ROMERO
  • Publication number: 20210128338
    Abstract: Technical garments including joint stabilization socks, sleeves, and other garments are disclosed. The exemplary garments disclosed herein include regions with material properties, such as tensile strengths, that are different from other regions of the garment. Particular regions of the exemplary garments include interwoven materials with substantially high tensile strengths for providing resistance/compression to targeted body parts (e.g., ankles, knees, shoulders, etc.) for preventing undesirable movement (e.g., that mimics medically-relevant taping patterns). In particular embodiments, the regions with higher tensile strengths are interwoven or integrated into a base material, such that the garment can be comfortably worn while also providing compression and support to targeted body parts.
    Type: Application
    Filed: August 22, 2018
    Publication date: May 6, 2021
    Inventors: Partha Sarathy UNNAVA, Tyler Jack Prescott HARMON
  • Publication number: 20200216551
    Abstract: The present invention discloses novel methods, compositions, and uses thereof for removing or overcoming immunosuppression. More specifically, the methods and compositions disclosed herein target effector Treg cells by modulating ST2 and/or IL-33 signaling using pharmaceutical inhibitors and/or genetic ablation, whereby the levels and/or activities of effector Treg cells in a tumor microenvironment are inhibited, and the infiltration of effector CD8+ cytotoxic T cells into tumor microenvironment increases. As a result, tumor growth is inhibited and tumor volume is reduced. The present invention also provides methods for identifying and isolating effector Treg cells in a population of heterogeneous cells.
    Type: Application
    Filed: January 6, 2020
    Publication date: July 9, 2020
    Inventors: Amy Li, Rebecca H. Herbst, Aviv Regev, Tyler Jacks, David Canner
  • Publication number: 20200078296
    Abstract: It has been discovered that lung tumor growth is associated with a dysregulation of the local microbiota, including an increased total bacterial load and reduced bacterial diversity in the airway. In the lungs, commensal bacteria, which are otherwise non-pathogenic and colonize pulmonary tissue at a much lower density in healthy individuals, provoke chronic inflammation and exacerbation of lung cancer through tumor-infiltrating immune cells. Thus, targeting the lung microbiota and its responding immune pathways is useful in treating lung cancer. Disclosed are compositions and methods targeting the lung microbiota and its responding immune pathways in a subject by specific targeting of commensal bacteria in the subject. Typically, the methods involve administering an effective amount of one or more therapeutics such as an antibiotic that reduces the local bacterial load, blocks or depletes tumor-infiltrating immune cells, and/or locally inhibits one or more cytokines or chemokines.
    Type: Application
    Filed: June 21, 2019
    Publication date: March 12, 2020
    Inventors: Chengcheng Jin, Georgia Lagoudas, Paul Blainey, Tyler Jacks
  • Publication number: 20190365719
    Abstract: It has been established that exposure to cytotoxic doses of HSP90 inhibitor is broadly immunosuppressive, whereas continuous exposure to low-dosages of the same inhibitor exerts anti-tumor activity. The anti-tumor activity is mediated by the host immune system. Compositions and methods for continuous, low-dose exposure to HSP90 inhibitors in combination with one or more immunostimulatory agents for the treatment of cancer are described. Typically, the HSP90 inhibitor is administered in an amount that is between 1% and 20% of the clinically-determined maximum tolerate dose. The immunostimulatory agent can be administered simultaneously with the HSP90 inhibitor, or at some time before or after the HSP90 inhibitor. Compositions including a sub-toxic dose of HSP90 inhibitor in combination with an immunostimulatory agent in an amount effective to treat cancer are also provided.
    Type: Application
    Filed: June 3, 2019
    Publication date: December 5, 2019
    Inventors: Tyler Jacks, Alexander Jaeger, Sandro Santagata, Luke Whitesell, Susan Lindquist
  • Patent number: 10206687
    Abstract: The present disclosure discusses systems and methods for controlling a hemorrhage. The hemorrhage control device can include a harness that is worn around an upper junctional area and a lower junctional area of a user. The hemorrhage control device can also include a compression device that is configured to reversibly couple with the harness. The compression device can include a compression puck and a handle. The handle can be coupled with the harness. When rotated the handle can constrict the harness around the upper junctional area or the lower junctional area. The constriction of the harness can also cause the compression puck to compress the upper junctional area or the lower junctional area.
    Type: Grant
    Filed: April 21, 2015
    Date of Patent: February 19, 2019
    Assignee: ARMR SYSTEMS LLC
    Inventors: Tyler Jack Prescott Harmon, Yegor Podgorsky, Chibueze Joseph Ihenacho
  • Publication number: 20170049459
    Abstract: The present disclosure discusses systems and methods for controlling a hemorrhage. The hemorrhage control device can include a harness that is worn around an upper junctional area and a lower junctional area of a user. The hemorrhage control device can also include a compression device that is configured to reversibly couple with the harness. The compression device can include a compression puck and a handle. The handle can be coupled with the harness. When rotated the handle can constrict the harness around the upper junctional area or the lower junctional area. The constriction of the harness can also cause the compression puck to compress the upper junctional area or the lower junctional area.
    Type: Application
    Filed: April 21, 2015
    Publication date: February 23, 2017
    Inventors: Tyler Jack Prescott Harmon, Yegor Podgorsky, Chibueze Joseph Ihenacho
  • Patent number: 7622630
    Abstract: Chimeric nonhuman mammals useful as inducible spontaneous cancer models are disclosed. The nonhuman mammals are obtained by introducing one or more genetically modified embryonic stem (ES) cells into an early stage embryo, and then implanting the manipulated embryo into a surrogate mother. The ES cells contain a recombinant oncogene, and also may contain a genetic mutation that deletes or inactivates a tumor suppressor gene. Models of different types of cancer are produced by introducing different combinations of genetic mutations into the ES cells that are introduced into the early stage embryo.
    Type: Grant
    Filed: August 27, 2004
    Date of Patent: November 24, 2009
    Assignee: AVEO Pharmaceuticals, Inc.
    Inventors: Joerg Heyer, Murray Robinson, William Rideout, III, Ronald Depinho, Steven C. Clark, Yinghui Zhou, Tyler Jacks, Ronan C. O'Hagan
  • Publication number: 20070292948
    Abstract: Chimeric nonhuman mammals useful as inducible spontaneous cancer models are disclosed. The nonhuman mammals are obtained by introducing one or more genetically modified embryonic stem (ES) cells into an early stage embryo, and then implanting the manipulated embryo into a surrogate mother. The ES cells contain a recombinant oncogene, and also may contain a genetic mutation that deletes or inactivates a tumor suppressor gene. Models of different types of cancer are produced by introducing different combinations of genetic mutations into the ES cells that are introduced into the early stage embryo.
    Type: Application
    Filed: August 27, 2004
    Publication date: December 20, 2007
    Applicant: GEN-PATH PHARMACEUTICALS, INC
    Inventors: Joerg Heyer, Murray Robinson, William Rideout, Ronald Depinho, Steven Clark, Yinghui Zhou, Tyler Jacks
  • Publication number: 20070025914
    Abstract: The present invention features stems cells from lungs, methods of isolating such stem cells, methods of diagnosing lung diseases, and method of treating lung diseases, including cancer, chronic obstructive pulmonary disease, cystic fibrosis, and emphysema.
    Type: Application
    Filed: June 15, 2006
    Publication date: February 1, 2007
    Inventors: Tyler Jacks, Carla Kim
  • Publication number: 20050080002
    Abstract: The present inventions features methods for treating or preventing cancer (e.g., cancer of the central nervous system) by administering a compound that inhibits PAK kinase activity and/or merlin phosphorylation to a mammal (e.g., a human). The invention also provides screening methods for identifying additional inhibitors of PAK kinase activity and/or merlin phosphorylation.
    Type: Application
    Filed: August 13, 2002
    Publication date: April 14, 2005
    Inventors: Tyler Jacks, Joseph Kissil
  • Publication number: 20050026878
    Abstract: The invention features methods for treating and preventing a peripheral nerve sheath tumor in a mammal such as a human. The methods involve administering to the mammal a compound that modulates the biological activity of a gonatropic steroid receptor, such as the progesterone receptor in an amount sufficient to inhibit the growth of the peripheral nerve sheath tumor. The mammal may be administered with the compound alone or in combination with a second therapeutic regimen. Also disclosed are screening methods that make use of gonatropic steroid receptors for the identification of novel therapeutics for PNSTs.
    Type: Application
    Filed: July 24, 2003
    Publication date: February 3, 2005
    Inventors: Margaret McLaughlin, Tyler Jacks
  • Patent number: D883651
    Type: Grant
    Filed: January 3, 2018
    Date of Patent: May 12, 2020
    Assignee: BETTER WALK, INC.
    Inventors: Tyler Jack Prescott Harmon, Partha Sarathy Unnava, Pranav Chunduri
  • Patent number: D890938
    Type: Grant
    Filed: August 22, 2018
    Date of Patent: July 21, 2020
    Assignee: BETTER WALK, INC.
    Inventors: Partha Sarathy Unnava, Tyler Jack Prescott Harmon
  • Patent number: D895815
    Type: Grant
    Filed: August 22, 2018
    Date of Patent: September 8, 2020
    Assignee: BETTER WALK, INC.
    Inventors: Partha Sarathy Unnava, Tyler Jack Prescott Harmon
  • Patent number: D905257
    Type: Grant
    Filed: April 7, 2020
    Date of Patent: December 15, 2020
    Assignee: BETTER WALK, INC.
    Inventors: Tyler Jack Prescott Harmon, Partha Sarathy Unnava, Pranav Chunduri